STEVEN B MILLER
Electrician at Vlg Gln Trl, Arlington, TX
License number
Texas 277718
Expiration Date
Feb 13, 2018
Category
Apprentice Electrician
Address
Address
3700 Village Glen Trl, Arlington, TX 76016
Phone
(817) 480-7339
Professional information
Use Of Hydroperoxyeicosatetraenoic Acid Derivatives Following Refractive Surgery
US Patent:
2002007, Jun 20, 2002
Filed:
Sep 27, 2001
Appl. No.:
09/965506
Inventors:
John Yanni - Burleson TX, US
Daniel Gamache - Arlington TX, US
Steven Miller - Arlington TX, US
Daniel Gamache - Arlington TX, US
Steven Miller - Arlington TX, US
Assignee:
Alcon Universal Ltd.
International Classification:
A61K031/22, A61K031/20, A61K031/16
US Classification:
514/549000, 514/560000, 514/626000, 514/627000
Abstract:
The use of HETE derivatives to treat dry eye conditions associated with refractive surgery is disclosed.
Use Of Connective Tissue Mast Cell Stabilizers To Facilitate Ocular Surface Re-Epithelization And Wound Repair
US Patent:
2008013, Jun 12, 2008
Filed:
Nov 29, 2007
Appl. No.:
11/947041
Inventors:
John M. Yanni - Burleson TX, US
Daniel A. Gamache - Arlington TX, US
Steven T. Miller - Arlington TX, US
Daniel A. Gamache - Arlington TX, US
Steven T. Miller - Arlington TX, US
Assignee:
ALCON MANUFACTURING LTD. - Fort Worth TX
International Classification:
A61K 31/55, A61K 31/335, A61K 31/519, A61K 31/505, A61K 31/4422
US Classification:
51421402, 514450, 5142581, 514256, 514356
Abstract:
Disclosed are methods of treating a wound in a subject that involve administering to the subject a pharmaceutically effective amount of a composition that includes one or more human connective tissue mast cell stabilizers, wherein administration of the composition results in treatment of the wound. In particular embodiments, the wound is an ophthalmic or dermal wound, such as a corneal epithelial defect, a conjunctival wound, or dermal abrasion. Administration, for example, may be by topical application of the composition to the ocular surface or skin. Exemplary mast cell stabilizers include olopatadine, variants of olopatadine, alcaftidine, derivatives of alcaftidine, dihydropyridines, and spleen tyrosine kinase inhibitors.
Rnai-Mediated Inhibition Of Spleen Tyrosine Kinase-Related Inflammatory Conditions
US Patent:
2011028, Nov 24, 2011
Filed:
Jun 30, 2011
Appl. No.:
13/172964
Inventors:
John M. Yanni - Burleson TX, US
Jon E. Chatterton - Fort Worth TX, US
Daniel A. Gamache - Arlington TX, US
Steven T. Miller - Arlington TX, US
Jon E. Chatterton - Fort Worth TX, US
Daniel A. Gamache - Arlington TX, US
Steven T. Miller - Arlington TX, US
Assignee:
ALCON RESEARCH, LTD. - Fort Worth TX
International Classification:
A61K 31/7105, A61P 27/02, A61K 31/713, A61P 29/00
US Classification:
514 44 A
Abstract:
RNA interference is provided for inhibition of spleen tyrosine kinase (Syk) mRNA expression, in particular, for treating patients having a Syk-related inflammatory condition or at risk of developing a Syk-related inflammatory condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, allergy, or mast-cell disease.
Use Of A Combination Of Olopatadine And Cilomilast To Treat Non-Infectious Rhinitis And Allergic Conjunctivitis
US Patent:
2009018, Jul 16, 2009
Filed:
Mar 18, 2009
Appl. No.:
12/406755
Inventors:
John M. Yanni - Burleson TX, US
Daniel A. Gamache - Arlington TX, US
Steven T. Miller - Arlington TX, US
Clay Beauregard - Fort Worth TX, US
Daniel A. Gamache - Arlington TX, US
Steven T. Miller - Arlington TX, US
Clay Beauregard - Fort Worth TX, US
Assignee:
Alcon Research, Ltd. - Fort Worth TX
International Classification:
A61K 31/335
US Classification:
514450
Abstract:
Disclosed are methods of treating allergic conjunctivitis and non-infectious rhinitis in a subject that involve topically administering to the subject a composition comprising olopatadine and cilomilast.
Rnai-Mediated Inhibition Of Tumor Necrosis Factor Alpha-Related Conditions
US Patent:
2013033, Dec 19, 2013
Filed:
Aug 22, 2013
Appl. No.:
13/973176
Inventors:
Jon E. Chatterton - Fort Worth TX, US
Diane Michelle Senchyna - Fort Worth TX, US
Daniel A. Gamache - Arlington TX, US
Steven T. Miller - Arlington TX, US
Diane Michelle Senchyna - Fort Worth TX, US
Daniel A. Gamache - Arlington TX, US
Steven T. Miller - Arlington TX, US
Assignee:
Alcon Research, Ltd. - Fort Worth TX
International Classification:
A61K 31/713, A61K 31/7088
US Classification:
514 44 A, 514 44 R
Abstract:
RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example.
Compositions Containing Hydroxyeicosatetraenoic Acid Derivatives And Methods Of Use In Treating Dry Eye Disorders
US Patent:
5696166, Dec 9, 1997
Filed:
Oct 31, 1995
Appl. No.:
8/551021
Inventors:
John M. Yanni - Burleson TX
Daniel A. Gamache - Arlington TX
Steven T. Miller - Arlington TX
Daniel A. Gamache - Arlington TX
Steven T. Miller - Arlington TX
International Classification:
A61K 3119, A61K 31215
US Classification:
514573
Abstract:
Compositions containing a HETE derivative and methods of use for treating dry eye are disclosed.
Method Of Preparing Human Conjunctival Mast Cells For Mast Cell Stabilization Assays
US Patent:
5360720, Nov 1, 1994
Filed:
Oct 8, 1993
Appl. No.:
8/134148
Inventors:
Steven T. Miller - Arlington TX
John M. Yanni - Burleson TX
John M. Yanni - Burleson TX
Assignee:
Alcon Laboratories, Inc. - Fort Worth TX
International Classification:
C12Q 102, C12Q 100, G01N 3353, G01N 33567
US Classification:
435 29
Abstract:
By allowing the mast cell enriched population of human conjunctival tissue cells to incubate for a minimum of about forty (40) hours post enzymatic digestion, the treatment window between spontaneous histamine release and anti-human IgE stimulated histamine release is increased. Culturing the human conjunctival tissue mast cells decreases the spontaneous release of histamine and increases the anti-IgE stimulated histamine release, greater than ten fold over spontaneous, at time points over forty (40) hours. This treatment window is sufficient to detect a compound's stabilizing or anti-allergic activity.
Compounds Which Inhibit Human Conjunctival Mast Cell Degranulation For Treating Ocular Allergic-Type Complications
US Patent:
6225327, May 1, 2001
Filed:
Oct 7, 1998
Appl. No.:
9/171045
Inventors:
Steven T. Miller - Arlington TX
Mark R. Hellberg - Arlington TX
John M. Yanni - Burleson TX
Mark R. Hellberg - Arlington TX
John M. Yanni - Burleson TX
Assignee:
Alcon Laboratories, Inc. - Fort Worth TX
Yamanouchi Pharmaceutical Co., Ltd. - Tokyo
Yamanouchi Pharmaceutical Co., Ltd. - Tokyo
International Classification:
A01N 4340
US Classification:
514342
Abstract:
Composition and methods for treating ocular allergic reactions are disclosed. In particular, the invention is directed to compounds which inhibit human conjunctival mast cell degranulation.
3,6-Substituted Imidazol[1,2-B]Pyridazine Analogs For Treating Allergic And Inflammatory Diseases
US Patent:
7713975, May 11, 2010
Filed:
Jan 12, 2006
Appl. No.:
11/330590
Inventors:
Mark R. Hellberg - Arlington TX, US
Steven T. Miller - Arlington TX, US
Andrew Rusinko - Arlington TX, US
Steven T. Miller - Arlington TX, US
Andrew Rusinko - Arlington TX, US
Assignee:
Alcon, Inc. - Hunenberg
International Classification:
A61K 31/50, A61K 31/501, C07D 237/26, C07D 487/00, C07D 235/00, C07D 233/00
US Classification:
51425201, 51425205, 544233, 544234, 544236, 5483017, 5483021, 5483111
Abstract:
Methods for treating an allergic or inflammatory disease or other Syk-mediated disease or Syk-mediated condition characterized by administering a composition which contains a therapeutically effective amount of a 3,6-substituted imidazol[1,2-b]pyridazine compound.
Methods Of Use Of Histamine H2 Agonists In Treating Dry Eye
US Patent:
6274160, Aug 14, 2001
Filed:
Apr 19, 2000
Appl. No.:
9/529837
Inventors:
Steven T. Miller - Arlington TX
Daniel A. Gamache - Arlington TX
John M. Yanni - Burleson TX
Daniel A. Gamache - Arlington TX
John M. Yanni - Burleson TX
Assignee:
Alcon Laboratories, Inc. - Fort Worth TX
International Classification:
A61K 906
US Classification:
424427
Abstract:
A topical ophthalmic composition for the treatment of dry eye in humans, comprising one or more histamine H. sub. 2 agonists, is disclosed.